A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Status:
Recruiting
Trial end date:
2031-02-09
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with
defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC
who have progressed on a prior platinum-based therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Verastem, Inc.
Collaborators:
European Network of Gynaecological Oncological Trial Groups (ENGOT) GOG Foundation